Kantar Health Blog

  • Stephanie Hawthorne
    In epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NCSLC), tyrosine kinase inhibitors (TKIs) such as Tarceva® (erlotinib, Genentech/Roche/Astellas) are the standard of care for first-line metastatic patients in the United States and Europe/Japan, respectively.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ASCO GU --- Prostate cancer is the most common cancer in men and the second most common cause of cancer deaths in men in the United States. The incident population of prostate cancer in the United States was above 200,000 patients in 2013. The rate of prostate cancer growth varies from very slow to moderately rapid, and some patients may have prolonged survival even after the cancer has metastasized to distant sites such as bone.
    Continue Reading > | Go comment! | Share
  • I-SPY 2 Graduates its First Experimental Regimen

    by Stephanie Hawthorne | Dec 13, 2013
    Stephanie Hawthorne
    Oncology Conference Insight: SABCS 2013 --- The I-SPY 2 trial is an innovative “find a winner” trial that aims to address some of these challenges by screening a number of different novel experimental agents in the neoadjuvant setting in combination with a standard chemotherapy regimen of paclitaxel followed by AC compared to standard chemotherapy alone. In this novel trial design, the randomization of patients to treatment arms is adaptive, with randomization probabilities continuing to be updated as the trial progressed.
    Continue Reading > | Go comment! | Share
  • Anastrozole: a new option for breast cancer chemoprevention?

    by Stephanie Hawthorne | Dec 13, 2013
    Stephanie Hawthorne
    Oncology Conference Insight: SABCS 2013 --- There are a variety of known risk factors for developing breast cancer, such as obesity, nulliparity, and age at time of menarche and menopause. For patients with a particularly high risk of developing breast cancer, including those who have a family history of the disease or have tested positive for deleterious BRCA1 or BRCA2 mutations, there are several options available for risk reduction. Currently, two hormonal agents, tamoxifen and raloxifene, are FDA approved to reduce the risk of breast cancer in patients at high risk of developing the disease.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: SABCS 2013 --- Endocrine therapy is a mainstay of therapy for breast cancer patients with estrogen receptor (ER) and/or progesterone receptor (PR) positive disease, with use in the adjuvant setting for early stage disease as well as in the metastatic setting. In the first-line metastatic setting, aromatase inhibitors (AI) can offer clinical benefit in post-menopausal ER+/PR+ patients, with progression-free survival (PFS) in clinical trials ranging from eight to 10 months.
    Continue Reading > | Go comment! | Share